Emcure makes a premium of 31.5 per cent over IPO price
Emcure's IPO ran from July 3 to July 5 and is a book-built issue valued at Rs 1,952.03 crores
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Market
Novo Holdings co-leads £90 million Series A financing for Myricx Bio
The funds will be used to build out Myricx Bio’s proprietary payload platform and advance its pipeline through clinical proof of…
Industry reports 76 deals worth $5B in June 2023: GlobalData
The pharma industry reported 88 VC deals worth $2.5B in June 2024, compared to the last 12-month (June 2023 to May 2024) average…
Submission of Nidlegy marketing authorisation application validated by EMA
The first marketing authorisation application of Nidlegy for the treatment of locally advanced fully resectable melanoma was…
Emcure Pharmaceuticals secures ₹582 crore from anchor investors
Investment comes at the upper price band of Rs. 1008 per share ahead of IPO opening
Amylyx looks to cover financial gap left by Relyvrio with avexitide deal, says GlobalData
The acquisition is a strategic action by Amylyx following the failure of its lead amyotrophic lateral sclerosis (ALS) therapy,…
Asthma inhaler price cap in US may help pharma companies to secure more loyal customer base:…
Pharmaceutical manufacturers like Boehringer Ingelheim, GSK, and AstraZeneca are participating in this initiative
Ayurveda market anticipated to hit $25 bn with international exports, says Dr Manoj Nesari
Exports are being made, particularly to the EU, UAE, and Japan, while other markets like Malaysia, Southeast Asia, and Taiwan are…
Alzheimer’s drug Leqembi launched by Eisai, Biogen in China
China is the third country to launch LEQEMBI following the US and Japan
Osteoporosis market to reach $17.9 bn across 7MM in 2033: GlobalData
With longer lifespans, its prevalence is expected to rise, necessitating a greater focus on bone health management and proactive…
FDA approval of CAPVAXIVE will enhance protection against pneumococcal disease in older adults:…
This is the first pneumococcal vaccine that is specifically designed to protect against serotypes which particularly infect older…
Dr Reddy’s to acquire Nicotinell and related portfolio
The portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol…
Cipla signs agreement with Takeda to commercialise Vonoprazan
This deal is meant to commercialise the drug in India under Cipla’s own trademark brands
FDA awards record number of review designations to mRNA vaccines in 2023: GlobalData
Following FDA approval in August 2021, Pfizer’s Comirnaty became the first mRNA vaccine to enter the global market, followed by…
Bayer’s BAY2927088 to face competition in EGFR-mutant but limited competition in HER2-exon 20 mutant…
BAY2927088 is an oral, tyrosine kinase inhibitor (TKI) that inhibits mutant HER2, including HER2 exon 20 insertions and HER2 point…
Sun Pharma completes Taro merger
Sun Pharma has been the majority shareholder of Taro since 2010
Vertex could solidify dominance in cystic fibrosis market with vanza triple approval: GlobalData
Vertex’s portfolio of cystic fibrosis transmembrane conductance, regulator modulators, including Kalydeco, Orkambi,…
Emcure Pharma receives SEBI nod for IPO
The company gears up for market debut with SEBI approval for Rs 800 Crore IPO
Indian domestic formulations market expected to more than double, comfortably crossing INR 5.5…
The report attempts a deep dive into understanding the evolution of the DomForm sector and its emergence as a largely BGx market
MSD Pharma to invest $38 million in Asia Pacific and Europe
Launched by MSD, IDEA Studios will be strategically located in asian and european innovation hubs to partner closely with…